All Oncology News

Fulzerasib plus cetuximab elicited deep efficacy in patients with KRAS G12C–mutated NSCLC enrolled in the phase 2 KROCUS study.

Adagrasib plus pembrolizumab continued to show promising efficacy in patients with KRAS G12C–mutated NSCLC and PD-L1 TPS of 50% or higher.

Gregory Roloff, MD, highlights ongoing frontline TKI research in Ph-positive ALL and why he uses a newer-generation TKI over imatinib.

Christopher L. Moertel, MD, discusses advances and ongoing research in NF1-associated plexiform neurofibromas.

Nirogacestat sustained long-term efficacy with acceptable safety in patients with desmoid tumors treated in the phase 3 DeFi trial.

Kelly E. McCann, MD, discusses mentorship, sponsorship, and work-life balance in oncology, highlighting strategies for supporting women in the field.

Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.

Tisotumab vedotin has received Japanese approval for advanced cervical cancer following chemotherapy.

Preclinical data showed that mutated cells can persist for years without becoming cancer and require additional inflammatory push for malignancy to occur.

The day-29 ORR and CR rate was not met with frontline itolizumab vs placebo in patients with acute graft-vs-host disease enrolled in the phase 3 EQUATOR trial.

Satya (Nanu) Das, MD, MSCI, pens this piece on what a career in drug development in the biopharmaceutical field may look like.

Amivantamab plus lazertinib provides long-term survival benefit over osimertinib in EGFR-mutated advanced non–small cell lung cancer.

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights advances in T-cell–redirecting therapies in the space.

Gregory Roloff, MD, details data on consolidation therapy with blinatumomab or CAR T-cell therapy for B-ALL, and the role of these agents in this setting.

TILT-123 plus pembrolizumab was active in platinum-resistant/refractory ovarian cancer in the phase 1a PROTA trial and the phase 1b portion is ongoing.

The addition of tumor treating fields to paclitaxel did not lead to a statistically significant overall survival improvement in platinum-resistant ovarian cancer.

Jaye Gardiner, PhD, postdoctoral fellow at Fox Chase Cancer Center to receive a grant from the nonprofit Uplifting Athletes during its Young Investigators Draft.

Findings from the safety review of SON-1010 plus trabectedin in patients with advanced leiomyosarcoma or liposarcoma were positive.

The investigational new drug application for the RDC SKB107 for the management of solid tumor bone metastases has been approved in China.

The FDA has approved cabozantinib (Cabometyx) for use in select patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Tess O’Meara, MD, MHS, and Kelsey H. Natsuhara, MD, discuss their presentations from the OncLive National Fellows Forum at SABCS.

Toon Van Gorp, MD, PhD, discusses the final analysis of the phase 3 MIRASOL trial of mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer.

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights symptom recognition and precursor conditions for the malignancy.

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Benjamin Herzberg, MD, highlights novel therapies in the KRAS-mutated NSCLC landscape and ongoing questions research is seeking to answer in this space.

Olalekan O. Oluwole, MD, discusses research findings showing that patients with LBCL may not need prolonged hospital monitoring following axi-cel infusion.

Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.

The development of nemvaleukin in platinum-resistant ovarian cancer will be discontinued based on interim OS data from the phase 3 ARTISTRY-7 trial.

Olvi-vec plus chemotherapy led to disease control in extensive-stage small cell lung cancer that was relapsed/refractory to platinum chemotherapy.

Nivolumab plus sunitinib displayed early-phase efficacy in advanced bone sarcoma.